Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
Reimbursement policy and androgen-deprivation therapy for prostate cancer
Vahakn B. Shahinian
,
Yong Fang Kuo
, Scott M. Gilbert
Biostatistics & Data Science
Research output
:
Contribution to journal
›
Article
›
peer-review
170
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Reimbursement policy and androgen-deprivation therapy for prostate cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Prostate Cancer
100%
Reimbursement Mechanisms
100%
Androgen Deprivation Therapy
100%
Year of Diagnosis
18%
Adjuvant Therapy
18%
Inappropriate Use
18%
Odds Ratio
18%
Confidence Interval
18%
Survival Benefit
18%
Primary Therapy
18%
Surveillance Epidemiology
9%
Evidence-based
9%
Radiation Therapy
9%
Medicare Database
9%
Substantial Change
9%
Reimbursement
9%
Low-to-moderate
9%
Localized Cancer
9%
American Cancer Society
9%
Modified Poisson Regression
9%
High-grade Tumor
9%
Medicare Reimbursement
9%
Locally Advanced Cancer
9%
Poisson Regression
9%
Medicare Modernization Act
9%
Nursing and Health Professions
Reimbursement
100%
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Medicare
27%
Odds Ratio
18%
Confidence Interval
18%
Adjuvant Therapy
18%
Advanced Cancer
9%
Radiotherapy
9%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Medicare
27%
Adjuvant Therapy
18%
Odds Ratio
18%
Malignant Neoplasm
9%
Cancer
9%
Surveillance, Epidemiology, and End Results
9%
Advanced Cancer
9%
Tumor
9%
Radiation Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Malignant Neoplasm
9%
Advanced Cancer
9%